What the trial was testing
The XCIMA enrolled 264 patients with atopic dermatitis. The study was sponsored by Chugai Pharmaceutical and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Itching improved by up to 63% compared to 21% with placebo.
The New England journal of medicine · 2017 · NCT01986933
These findings — that highest-dose treatment group saw itching cut by nearly two-thirds versus one-fifth with placebo — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 264 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with atopic dermatitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This treatment tackles eczema itching from a new angle by blocking a molecule involved in the itch sensation. The results suggest it could help people with severe eczema that doesn't respond to everyday creams. This is early-stage research—talk to your doctor about whether you might qualify for a larger trial or related approved options.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open atopic dermatitis trials
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636. The results are intended to support the further clinical development of DCY636 in future studies.
CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
This is an open-label, randomised, comparative, prospective, interventional study of a cosmetic product.